Register Login
Register to leave comments
  • News bot Oct. 28, 2025, 8:11 p.m.

    📋 Arcus Biosciences, Inc. (RCUS) - Clinical Trial Update

    Filing Date: 2025-10-28

    Accepted: 2025-10-28 16:08:48

    Event Type: Clinical Trial Update

    Event Details:

    Arcus Biosciences Inc. (RCUS) Announces Clinical Trial Update Arcus Biosciences Inc. (RCUS) provided an update on its clinical development programs. Clinical Development Highlights:
    • Clinical Stage: Phase 2, Phase 3
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Patient Enrollment, Regulatory Process
    • Collaboration: PFS
      • targeting inflammatory and autoimmune diseases; a small molecule targeting MRGPRX2 is in preclinical development and expected to enter the clinic in 2026
      • expected in 2026

    🔬 Clinical Development Pipeline (Arcus Biosciences, Inc.):

    Product Type Development Stage Therapeutic Area Source
    Gemcitabine DRUG Phase PHASE3 Metastatic Pancreatic Ductal Adenocarcinoma ClinicalTrials.gov
    casdatifan DRUG Phase PHASE1 Clear Cell Renal Cell Carcinoma ClinicalTrials.gov
    Zimberelimab DRUG Phase PHASE1 Metastatic Colorectal Cancer ClinicalTrials.gov
    Paclitaxel DRUG Phase PHASE2 Non Small Cell Lung Cancer ClinicalTrials.gov
    Nab-paclitaxel DRUG Phase PHASE3 Metastatic Pancreatic Ductal Adenocarcinoma ClinicalTrials.gov
    Domvanalimab DRUG Phase PHASE2 Non Small Cell Lung Cancer ClinicalTrials.gov
    Cabozantinib DRUG Phase PHASE1 Clear Cell Renal Cell Carcinoma ClinicalTrials.gov
    Regorafenib DRUG Phase PHASE1 Metastatic Colorectal Cancer ClinicalTrials.gov
    m-FOLFOX-6 regimen DRUG Phase PHASE1 Metastatic Colorectal Cancer ClinicalTrials.gov
    Bevacizumab DRUG Phase PHASE1 Metastatic Colorectal Cancer ClinicalTrials.gov
    Etrumadenant DRUG Phase PHASE1 Metastatic Colorectal Cancer ClinicalTrials.gov
    AB680 DRUG Phase PHASE1 Metastatic Colorectal Cancer ClinicalTrials.gov
    Pembrolizumab DRUG Phase PHASE2 Non Small Cell Lung Cancer ClinicalTrials.gov
    Pemetrexed DRUG Phase PHASE2 Non Small Cell Lung Cancer ClinicalTrials.gov
    Carboplatin DRUG Phase PHASE2 Non Small Cell Lung Cancer ClinicalTrials.gov
    Nivolumab DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    Avelumab DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    Aldesleukin DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    AU-007 DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    Placebo DRUG Phase EARLY_PHASE1 Glioblastoma ClinicalTrials.gov
    Quemliclustat DRUG Phase PHASE3 Metastatic Pancreatic Ductal Adenocarcinoma ClinicalTrials.gov
    Oxaliplatin DRUG Phase PHASE1 Advanced Cancer ClinicalTrials.gov
    Leucovorin DRUG Phase PHASE1 Advanced Cancer ClinicalTrials.gov
    Fluorouracil DRUG Phase PHASE1 Advanced Cancer ClinicalTrials.gov
    AB598 DRUG Phase PHASE1 Advanced Cancer ClinicalTrials.gov
    Capecitabine DRUG Phase PHASE3 Advanced Upper Gastrointestinal Tract Adenocarcinoma ClinicalTrials.gov
    Genetic: MB-105 BIOLOGICAL Phase PHASE2 Lymphoma, T-Cell ClinicalTrials.gov
    Docetaxel DRUG Phase PHASE1 Advanced Cancer ClinicalTrials.gov
    AB801 DRUG Phase PHASE1 Advanced Cancer ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Arcus Biosciences Inc.
    • CIK: 0001724521
    • Ticker Symbol: RCUS
    • Period End Date: 2025-10-28
    • Document Type: 8-K

Search

News categories